Exisulind
WikiDoc Resources for Exisulind |
Articles |
---|
Most recent articles on Exisulind |
Media |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Exisulind at Clinical Trials.gov Clinical Trials on Exisulind at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Exisulind
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Exisulind Discussion groups on Exisulind Directions to Hospitals Treating Exisulind Risk calculators and risk factors for Exisulind
|
Healthcare Provider Resources |
Causes & Risk Factors for Exisulind |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
Exisulind is a drug used to treat cancer. It acts by inhibiting the enzyme cyclic guanosine monophosphate phosphodiesterase. Tademark by OSI Pharmaceuticals is Aptosyn.